*EA2182 / RGIC19164 / DECREASE / Haoming Qiu
Research Question:
How well does lower-dose chemotherapy plus radiation therapy (chemoradiation) work
in comparison to standard-dose chemoradiation in treating patients with early-stage
anal cancer?
Basic Study Information
Purpose:
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation)
therapy works in comparison to standard-dose chemoradiation in treating patients with
early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil,
and capecitabine, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving
chemotherapy with radiation therapy may kill more tumor cells. This study may help
doctors find out if lower-dose chemoradiation is as effective and has fewer side effects
than standard-dose chemoradiation, which is the usual approach for treatment of this
cancer type.
Location: University of Rochester Medical Center
Study Reference #: RGIC19164
Lead Researcher (Principal Investigator)
Lead Researcher:
Haoming Qiu
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search